First Manhattan CO Concert Pharmaceuticals, Inc. Transaction History

First Manhattan CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 16, 2019	SELL	$9.44 - $13.12 $4.28 Million - $5.94 Million	-453,091 Closed	0 $0
Q1 2019 Apr 12, 2019	SELL	$12.07 - $17.54 $7.2 Million - $10.5 Million	-596,443 Reduced 56.83%	453,091 $5.47 Million
Q4 2018 Jan 30, 2019	BUY	$11.25 - $16.17 $5.45 Million - $7.84 Million	484,739 Added 85.83%	1,049,534 $13.2 Million
Q3 2018 Oct 15, 2018	BUY	$12.82 - $17.88 $7.24 Million - $10.1 Million	564,795 New	564,795 $8.38 Million
Q1 2018 Apr 20, 2018	SELL	$19.24 - $28.03 $344,396 - $501,737	-17,900 Closed	0 $0
Q4 2017 Jan 22, 2018	SELL	$13.96 - $29.05 $711,960 - $1.48 Million	-51,000 Reduced 74.02%	17,900 $463,000
Q3 2017 Oct 25, 2017	BUY	$13.91 - $15.31 $958,399 - $1.05 Million	68,900	68,900 $1.02 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.